JW Holdings Corp is a Korea-based company principally engaged in the production and sale of pharmaceuticals. The Company is principally engaged in the production and sale of pharmaceuticals such as antibiotics, antifungal agents, blood and body fluids substitutes, hyperlipidemia drugs, electrolyte additives, angina pills and digestive medicines. The Company is also engaged in the manufacture and sale of diagnostic equipment for hematology, immunology and others. In addition, the Company is engaged in the holding businesses.

Employees

114

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
18/09/26	₩4,330.00	0.00%	221,397
17/09/26	₩4,330.00	+1.17%	96,606
16/09/26	₩4,280.00	0.00%	85,358
15/09/26	₩4,280.00	+0.23%	40,498
14/09/26	₩4,270.00	0.00%	84,692

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 18/09/2026			5-day change	1st Jan Change
4,330.00 ^KRW	0.00%		+1.41%	+20.61%

08-14	JW Holdings Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	JW Holdings Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	300B 216M 188M 178M 161M 302M 20.69B 303M 2.13B 821M 10.52B 810M 792M 33.85B	P/E 2024	3.45x	P/E 2025	4.27x
Enterprise Value	570B 410M 358M 338M 307M 574M 39.35B 577M 4.04B 1.56B 20.01B 1.54B 1.51B 64.37B	EV / Sales 2024	0.65x	EV / Sales 2025	0.53x
Free-Float	41.06%	Yield 2024	5.13%	Yield 2025	-

08-14	JW Holdings Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	JW Holdings Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-13	JW Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-05	JW Holdings Corporation announces Annual dividend, payable on April 24, 2026	CI
11-14	JW Holdings Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-03	Jw Holdings Q3 operating profit 5 billion won, up 38.4% from year earlier	RE
14/08/25	JW Holdings Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
31/07/25	Jw Holdings Q2 operating profit 3.4 billion won, down 82% from year earlier	RE
04/07/25	Sound Smithy Co Ltd announced that it has received KRW 200 million in funding from JW Holdings Corporation	CI
26/06/25	Sound Smithy Co Ltd announced that it expects to receive KRW 200 million in funding from JW Holdings Corporation	CI
25/06/25	Tranche Update on JW Holdings Corporation's Equity Buyback Plan announced on March 24, 2025.	CI
25/06/25	Tranche Update on JW Holdings Corporation's Equity Buyback Plan announced on March 24, 2025.	CI
24/06/25	JW Holdings Corporation's Equity Buyback announced on March 24, 2025 has expired with 714,439 shares, representing 1.02% for KRW 2,500 million.	CI

04/10/23	Les valeurs à suivre aujourd'hui à la Bourse de Paris - Mercredi 4 octobre 2023
04/10/23	Kering : Seán McGirr nommé Directeur de la Création d'Alexander McQueen
03/10/23	Kering : nouveau directeur création chez Alexander McQueen
03/10/23	Kering nomme Seán McGirr directeur de la création chez Alexander McQueen
18/08/23	El Kospi de Corea cae un 0,6%, su mayor racha de pérdidas desde junio de 2022 -- Market Talk

JW Holdings Corporation Stock

Stocks

A096760

KR7096760004

Pharmaceuticals

Valuation: JW Holdings Corporation

Chart: JW Holdings Corporation

Latest news: JW Holdings Corporation

News in other languages: JW Holdings Corporation

Quotes and Performance

Price Extremes

Managers and Directors: JW Holdings Corporation

Latest insider transactions

Generic Pharmaceuticals

Financials

Company Profile

Quotes

1 week	+1.41%
Current month	+4.84%
1 month	+8.93%
3 months	+14.25%
6 months	+1.05%
Current year	+20.61%

1 week	4,200	4,500
1 month	3,920	4,500
Current year	3,300	4,720
1 year	3,145	4,720
3 years	2,650	4,720
5 years	2,536.65	4,720
10 years	2,536.65	16,326.2

Manager	Title	Age	Since
Seong-Nam Cha CEO	Chief Executive Officer	69	27/03/2024
Kyung-Ha Lee CEO	Chief Executive Officer	63	-
Ji-Woo Choi DFI	Director of Finance/CFO	60	27/03/2020

Director	Title	Age	Since
Kyung-Ha Lee CHM	Chairman	63	-
Chan-Yeop Yeom BRD	Director/Board Member	64	27/03/2020
Ji-Woo Choi BRD	Director/Board Member	60	27/03/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
07/02/24	Sung-Kweon Han	Free	Chief Executive Officer	215	0.0003%
07/02/24	Gui-eung Song	Free		4	0.0000%	-
07/02/24	Kyung-Ha Lee	Free	Chief Executive Officer	412,069	0.5574%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JW HOLDINGS CORPORATION	0.00%	+1.41%	+29.25%	+7.72%	216M
SUN PHARMACEUTICAL INDUSTRIES LTD.	-1.61%	-0.15%	+10.95%	+60.09%	45.94B
OTSUKA HOLDINGS CO., LTD.	-1.02%	-1.90%	+36.59%	+99.64%	37.22B
ZYDUS LIFESCIENCES LIMITED	+2.19%	+3.65%	+11.83%	+80.29%	12.06B
CIPLA LIMITED	+1.32%	+2.09%	-11.51%	+12.41%	11.74B
KRKA, D. D.	-0.95%	0.00%	+19.27%	+141.86%	9.03B
GEDEON RICHTER	+0.39%	+2.39%	+31.05%	+39.38%	7.36B
GLENMARK PHARMACEUTICALS LIMITED	+1.30%	+1.17%	+17.37%	+187.41%	7.2B
ONO PHARMACEUTICAL CO., LTD.	-0.06%	+2.97%	+39.67%	-18.37%	7.15B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+0.70%	+1.10%	-41.96%	+5.34%	5.03B
Average	+0.23%	+1.12%	+14.25%	+61.58%	14.29B
Weighted average by Cap.	-0.44%	+0.23%	+17.34%	+72.76%

	2024	2025
Net sales	888B 639M 557M 526M 478M 895M 61.31B 899M 6.3B 2.43B 31.17B 2.4B 2.35B 100B	970B 698M 609M 575M 522M 978M 66.97B 982M 6.88B 2.66B 34.05B 2.62B 2.56B 110B
Net income	62.62B 45.07M 39.3M 37.11M 33.7M 63.14M 4.33B 63.4M 445M 172M 2.2B 169M 166M 7.08B	58.5B 42.11M 36.72M 34.67M 31.49M 58.99M 4.04B 59.24M 415M 160M 2.05B 158M 155M 6.61B
Net Debt	362B 260M 227M 214M 195M 365M 24.98B 366M 2.57B 991M 12.7B 978M 956M 40.87B	270B 194M 170M 160M 145M 272M 18.66B 273M 1.92B 740M 9.48B 730M 714M 30.52B